仿制同型基因GDF15蛋白质的单环合体的设计,以抑制GDF15-GFRaL-RET复杂细胞信号传递
Anaïs F M Noisier, Jenny Sandmark, Fredrik Edfeldt
1BicycleTx Limited, Portway Building, Granta Park, Cambridge CB21 6GS, U.K.
Journal of medicinal chemistry
|October 9, 2025
概括
研究人员开发了针对GDF15-GFRaL-RET通路的新型抑制剂. 这些自行车分子模仿GDF15的GDF15.
科学领域:
- 生物化学和分子生物学
- 药物发现和开发 药物发现和开发
背景情况:
- 质细胞系衍生神经缩因子 (GDNF) 家庭受体α-Like (GFRaL) 和生长分化因子15 (GDF15) 与RET受体氨酸激酶形成复合体,调节关键细胞过程.
- GDF15-GFRaL-RET通路的调节失调与代谢障碍,癌症和消耗性疾病 (如缓冲症) 有关.
研究的目的:
- 发现和开发破坏GDF15-GFRaL蛋白质与蛋白质相互作用的有力抑制剂.
- 通过准GDF15-GFRaL复合体形成来防止异常的RET诱导信号.
主要方法:
- 使用结构导向设计和菌体显示来识别针对GFRaL.L的高亲和度双循环.
- 基聚合物被二聚化以创建串联自行车分子,模仿同型二聚体GDF15.5的双聚体结合.
- 使用功能性测试来评估细胞信号的抑制和开发的分子的药理动力学特性.
主要成果:
- 菌体显示产生了对GFRaL的高度亲和度高的双循环.
- 经二元化 自行车分子实现了比科莫尔亲缘关系,与内源性GDF15.6相比.
- 这些新型分子表现出细胞信号的抑制,并改善了与单体类相比的药物动力学概况.
结论:
- 这项研究介绍了第一个能够抑制GDF15-GFRaL受体复合体形成的同位素自行车分子.
- 这代表了一种新的治疗策略,用于对抗由GDF15-GFRaL-RET通路介导的细胞内信号响应.
- 开发的抑制剂有可能治疗与GDF15通路失调相关的疾病,包括代谢障碍和癌症.
更多相关视频
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
7.3K
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
12.4K
相关概念视频
TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
G Protein-coupled Receptors
16.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.5K
Amplifying Signals via Enzymatic Cascade
17.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.3K
Glucagon-like Receptor Agonists
841
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
841
